BioAtla receives FDA fast track designation for ozuriftamab vedotin
The Phase II antibody drug conjugate received FDA fast track designation against treatment-resistant head and neck carcinoma.
The Phase II antibody drug conjugate received FDA fast track designation against treatment-resistant head and neck carcinoma.
What's Your Reaction?
